6/27/23, 11:49 PM BrigHTN (baxdrostat 2 mg) Pathway Feedback Search Clinical Topics Home Studies BrigHTN (baxdrostat 2 mg) BrigHTN (baxdrostat 2 mg) Disease Hypertension Trial question What is the role of high-dose baxdrostat in patients with treatment-resistant hypertension? Study design Multi-center Double blinded RCT Population Characteristics of study participants 41.0% female N = 136 59.0% male 136 patients (56 female, 80 male) Inclusion criteria: patients who had treatment-resistant hypertension, with BP 130/80 mmHg, and who were receiving stable doses of at least three antihypertensive agents, including a diuretic Key exclusion criteria: mean seated systolic BP of at least 180 mmHg or diastolic BP of at least 110 mmHg; an eGFR of < 45 mL/min/1.73 m ; uncontrolled diabetes Interventions N=67 baxdrostat (at a dose of 2 mg daily for 12 weeks) N=69 placebo (matching placebo for 12 weeks) Primary outcome Reduction in systolic blood pressure at week 12 20.3 mmHg 20.3 https://web.pathway.md/studies/rec67ZBEe4bP5GO2i 1/2 6/27/23, 11:49 PM BrigHTN (baxdrostat 2 mg) Pathway 15.2 mmHg 10.2 mmHg 9.4 5.1 mmHg Significant increase 0.0 mmHg Baxdrostat Placebo Significant increase in reduction in systolic BP at week 12 (20.3 mmHg vs. 9.4 mmHg; AD 11 mmHg, 95% CI 5.5 to 16.4) Secondary outcomes Significant increase in reduction in diastolic BP at week 12 (14.3 mmHg vs. 9.2 mmHg; AD 5.2 mmHg, 95% CI 1.6 to 8.7) Safety outcomes No significant difference in adverse events. Conclusion In patients who had treatment-resistant hypertension, with BP 130/80 mmHg, and who were receiving stable doses of at least three antihypertensive agents, including a diuretic, baxdrostat was superior to placebo with respect to reduction in systolic BP at week 12. Reference Mason W Freeman, Yuan-Di Halvorsen, William Marshall et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. Open reference URL https://web.pathway.md/studies/rec67ZBEe4bP5GO2i 2/2